| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Date of Product Approval | Product | Federal Register Date | PRV Issuance URL | PRV Recipient | PRV Buyer or Redeeming Sponsor (if known) | Payment (if known) | PRV Transaction Date (if known) | Transaction URL | DIFF between PRV Issued Date and PRV Transaction Date | ||||||||||||||||
2 | 04/07/2009 | Coartem (artemether/lumefantrine) | - | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_SumR.pdf | Novartis | Novartis | - | - | - | |||||||||||||||||
3 | 12/28/2012 | Sirturo (bedaquiline) | - | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384Orig1s000ltr.pdf | Janssen (JNJ) | Janssen (JNJ) | - | - | - | |||||||||||||||||
4 | 02/14/2014 | VIMIZIM (elosulfase alfa) | 03/12/2014 | https://www.govinfo.gov/content/pkg/FR-2014-03-12/pdf/2014-05410.pdf | BioMarin Pharmaceutical, Inc | Regeneron Ireland | $67,500,000 | 07/29/2014 | https://www.sec.gov/Archives/edgar/data/1048477/000119312514384895/d798950dex101.htm | 165 | ||||||||||||||||
5 | 03/19/2014 | Impavido (miltefosine) | - | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204684Orig1s000ltr.pdf | Paladin/Knight | Gilead | $125,000,000 | 11/19/2014 | https://www.biospace.com/article/knight-therapeutics-sells-priority-review-voucher-to-gilead-sciences-inc-for-us-125-million-cash-/ | 245 | ||||||||||||||||
6 | 03/10/2015 | UNITUXIN (dinutuximab) | 04/07/2015 | https://www.govinfo.gov/content/pkg/FR-2015-04-07/pdf/2015-08014.pdf | United Therapeutics Corporation | AbbVie | $350,000,000 | 08/19/2015 | https://www.sec.gov/Archives/edgar/data/1082554/000110465915060788/a15-18206_1ex99d1.htm | 162 | ||||||||||||||||
7 | 03/17/2015 | CHOLBAM (cholic acid) | 04/07/2015 | https://www.govinfo.gov/content/pkg/FR-2015-04-07/pdf/2015-08016.pdf | Asklepion/Retrophin | Sanofi | $245,000,000 | 05/22/2015 | https://www.sec.gov/Archives/edgar/data/1438533/000119312515201124/d932773dex21.htm | 66 | ||||||||||||||||
8 | 09/04/2015 | Xuriden (uridine triacetate) | 09/29/2015 | https://www.govinfo.gov/content/pkg/FR-2015-09-29/pdf/2015-24640.pdf | Wellstat Therapeutics Corp | |||||||||||||||||||||
9 | 10/23/2015 | STRENSIQ (asfotase alfa) | 11/17/2015 | https://www.govinfo.gov/content/pkg/FR-2015-11-17/pdf/2015-29280.pdf | Alexion Pharmaceuticals | Alexion Pharmaceuticals | - | - | - | |||||||||||||||||
10 | 12/08/2015 | KANUMA (sebelipase alfa) | 07/01/2019 | https://www.govinfo.gov/content/pkg/FR-2019-07-01/pdf/2019-13944.pdf | Alexion Pharmaceuticals | - | - | - | - | |||||||||||||||||
11 | 06/10/2016 | Vaxchora | - | https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxchora | PaxVax | Gilead | $200,000,000 | - | several reports | |||||||||||||||||
12 | 09/19/2016 | EXONDYS 51 (eteplirsen) | 10/17/2016 | https://www.govinfo.gov/content/pkg/FR-2016-10-17/pdf/2016-24947.pdf | Sarepta Therapeutics | Gilead | $125,000,000 | 02/20/2017 | https://www.sec.gov/Archives/edgar/data/873303/000156459017008747/srpt-ex101_27.htm | 154 | ||||||||||||||||
13 | 12/23/2016 | SPINRAZA (nusinersen) | 03/06/2017 | https://www.govinfo.gov/content/pkg/FR-2017-03-06/pdf/2017-04228.pdf | Biogen | |||||||||||||||||||||
14 | 02/09/2017 | EMFLAZA (deflazacort) | 04/25/2017 | https://www.govinfo.gov/content/pkg/FR-2017-04-25/pdf/2017-08309.pdf | Marathon Pharmaceuticals, LLC | ViiV Healthcare | ||||||||||||||||||||
15 | 04/27/2017 | Brineura (cerliponase alfa) | 06/26/2017 | https://www.govinfo.gov/content/pkg/FR-2017-06-26/pdf/2017-13236.pdf | Biomarin Pharmaceuticals Inc | Novartis | $125,000,000 | 11/21/2017 | https://www.sec.gov/Archives/edgar/data/1048477/000156459018003114/bmrn-ex1047_294.htm | 208 | ||||||||||||||||
16 | 08/29/2017 | Benznidazole | - | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209570Orig1s000ltr.pdf | Chemo Research | Novo Nordisk | ||||||||||||||||||||
17 | 11/15/2017 | MEPSEVII (vestronidase alfa-vjbk) | 12/15/2017 | https://www.govinfo.gov/content/pkg/FR-2017-12-15/pdf/2017-27049.pdf | Ultragenyx Pharmaceutical | Novartis | $130,000,000 | 12/18/2017 | https://www.sec.gov/Archives/edgar/data/1515673/000156459017025027/rare-ex991_6.htm | 33 | ||||||||||||||||
18 | 12/19/2017 | LUXTURNA (voretigene neparvovec) | 01/02/2018 | https://www.govinfo.gov/content/pkg/FR-2018-01-02/pdf/2017-28256.pdf | Spark Therapeutics | Jazz Pharmaceuticals | $110,000,000 | 04/30/2018 | https://sparktx.com/press_releases/spark-therapeutics-sells-priority-review-voucher-for-110-million/ | 132 | ||||||||||||||||
19 | 02/12/2018 | SYMDEKO (tezacaftor/ivacaftor) | 03/29/2019 | https://www.govinfo.gov/content/pkg/FR-2019-03-29/pdf/2019-06138.pdf | Vertex Pharmaceutical | |||||||||||||||||||||
20 | 04/17/2018 | CRYSVITA (burosamab-twza) | 08/15/2018 | https://www.govinfo.gov/content/pkg/FR-2018-08-15/pdf/2018-17527.pdf | Ultragenyx Pharmaceutical, Inc | Gilead | $80,600,000 | 06/01/2018 | http://ir.ultragenyx.com/node/12186/html | 45 | ||||||||||||||||
21 | 05/01/2018 | KYMRIAH (tisagenlecleucel) | 09/11/2017 | https://www.govinfo.gov/content/pkg/FR-2017-09-11/pdf/2017-19130.pdf | Novartis | - | - | - | - | |||||||||||||||||
22 | 06/13/2018 | Moxidectin | - | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210867Orig1s000Ltr.pdf | Medicines Development | Novo Nordisk | ||||||||||||||||||||
23 | 06/25/2018 | EPIDIOLEX (cannabidiol oral solution) | 07/19/2018 | https://www.govinfo.gov/content/pkg/FR-2018-07-19/pdf/2018-15393.pdf | GW Research Ltd | Biohaven Pharmaceutical | $105,000,000 | 03/15/2019 | https://www.sec.gov/Archives/edgar/data/1351288/000156459019016648/gwph-ex101_76.htm | 263 | ||||||||||||||||
24 | 07/13/2018 | TPOXX (tecovirimat) | 04/01/2019 | https://www.govinfo.gov/content/pkg/FR-2019-04-01/pdf/2019-06145.pdf | SIGA Technologies, Inc | Eli Lilly | $80,000,000 | 11/01/2018 | https://www.sec.gov/Archives/edgar/data/1010086/000114036118042027/ex99_1.htm | 111 | ||||||||||||||||
25 | 07/20/2018 | Krintafel | - | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210795Orig1s000Approv.pdf | GSK | ViiV Healthcare | ||||||||||||||||||||
26 | 10/05/2018 | REVCOVI (elapegademase-lvlr) | 10/25/2018 | https://www.govinfo.gov/content/pkg/FR-2018-10-25/pdf/2018-23308.pdf | Leadiant Bioscience Inc | |||||||||||||||||||||
27 | 11/20/2018 | GAMIFANT (emapalumab-lzsg) | 12/13/2018 | https://www.govinfo.gov/content/pkg/FR-2018-12-13/pdf/2018-27043.pdf | Novimmune/Sobi | AstraZeneca | $95,000,000 | 08/22/2019 | https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019.html | 275 | ||||||||||||||||
28 | 02/13/2019 | Egaten | - | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208711Orig1s000ltr.pdf | Novartis | - | - | - | - | |||||||||||||||||
29 | 05/01/2019 | Dengvaxia | - | https://www.fda.gov/media/124402/download | Sanofi | - | - | - | - | |||||||||||||||||
30 | 05/24/2019 | ZOLGENSMA (onasemnogene abeparvovec-xioi) | 06/24/2019 | https://www.govinfo.gov/content/pkg/FR-2019-06-24/pdf/2019-13356.pdf | AveXis, Inc | |||||||||||||||||||||
31 | 08/14/2019 | Pretomanid | - | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Approv.pdf | TB Alliance | |||||||||||||||||||||
32 | 09/24/2019 | JYNNEOS, (Smallpox and Monkeypox Vaccine, Live, Non-replicating) | 10/09/2019 | https://www.govinfo.gov/content/pkg/FR-2019-10-09/pdf/2019-21984.pdf | Bavarian Nordic A/S | undisclosed | $95,000,000 | 12/17/2019 | http://www.bavarian-nordic.com/investor/news/news.aspx?news=5887 | 84 | ||||||||||||||||
33 | 10/21/2019 | Trikafta | 9/15/2020 | https://www.federalregister.gov/documents/2020/09/15/2020-20320/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Vertex | |||||||||||||||||||||
34 | 12/12/2019 | VYONDYS 53 (golodirsen) | 01/23/2020 | https://www.govinfo.gov/content/pkg/FR-2020-01-23/pdf/2020-01059.pdf | Sarepta Therapeutics, Inc | Vifor Pharma | $108,100,000 | 02/17/2020 | https://www.sec.gov/ix?doc=/Archives/edgar/data/873303/000156459020021905/srpt-10q_20200331.htm | 67 | ||||||||||||||||
35 | 12/19/2019 | Ervebo | - | https://www.fda.gov/media/133757/download | Merck | - | - | - | - | |||||||||||||||||
36 | 4/10/2020 | Koselugo | 9/16/2020 | https://www.federalregister.gov/documents/2020/09/16/2020-20387/issuance-of-priority-review-voucher-rare-pediatric-disease-product | AstraZeneca Pharmaceuticals, LP | |||||||||||||||||||||
37 | 8/7/2020 | Evrysdi | 8/25/2020 | https://www.federalregister.gov/documents/2020/08/25/2020-18648/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Genentech Inc. | |||||||||||||||||||||
38 | 8/12/2020 | Viltepso | 9/4/2020 | https://www.federalregister.gov/documents/2020/09/04/2020-19604/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Nippon Shinyaku Co., Ltd. (NS Pharma Inc., U.S. Agent) | |||||||||||||||||||||
39 | 11/20/2020 | Zokinvy | 12/17/2020 | https://www.federalregister.gov/documents/2020/12/17/2020-27778/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Eiger BioPharmaceuticals, Inc. | |||||||||||||||||||||
40 | 11/23/2020 | Oxlumo | 2/16/2021 | https://www.federalregister.gov/documents/2021/02/16/2021-03012/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Alnylam Pharmaceuticals Inc. | |||||||||||||||||||||
41 | 11/25/2020 | Imcivree | 12/17/2020 | https://www.federalregister.gov/documents/2020/12/17/2020-27760/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Rhythm Pharmaceuticals, Inc. | |||||||||||||||||||||
42 | 11/25/2020 | Danyelza | 12/07/2020 | https://www.federalregister.gov/documents/2020/12/07/2020-26801/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Y-mAbs Therapeutics, Inc., (Cato Research LLC., US Agent) | |||||||||||||||||||||
43 | 2/25/2021 | Amondys 45 | 3/12/2021 | https://www.federalregister.gov/documents/2021/03/12/2021-05208/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Sarepta Therapeutics Inc. | |||||||||||||||||||||
44 | 2/26/2021 | Nulibry | 3/12/2021 | https://www.federalregister.gov/documents/2021/03/12/2021-05207/issuance-of-priority-review-voucher-rare-pediatric-disease-product | Origin Biosciences, Inc. | |||||||||||||||||||||
45 | ||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||
47 | max | $350,000,000 | ||||||||||||||||||||||||
48 | min | $67,500,000 | ||||||||||||||||||||||||
49 | average | $136,080,000 | ||||||||||||||||||||||||
50 | median | $110,000,000 |